Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702 (Cevira)
Oslo, Norway, 11 November, 2020: Photocure ASA (OSE:PHO) today announces that its partner Asieris Pharmaceuticals has initiated the phase III clinical trial for APL-1702 (Cevira[®]), triggering a USD 1.5 million milestone payment under the global licensing deal.“The initiation of the phase III clinical trial for Cevira is an important milestone towards a non-surgical treatment of high-grade cervical dysplasia. Our partner Asieris is making great progress and is on track with their clinical program and development of this innovative photodynamic drug-device combination,” says Daniel